SOURCE: Depomed, Inc.

February 08, 2011 08:00 ET

Depomed to Present at the 13th Annual BIO CEO & Investor Conference

MENLO PARK, CA--(Marketwire - February 8, 2011) - Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 13th Annual BIO CEO & Investor Conference in New York City on February 15, 2011 at 8:30 am EST.

The company will be webcasting its presentation and interested parties can access the live or archived presentation for up to 90 days on the company's website at

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and has developed another approved product. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. GRALISE™ (gabapentin) is a once-daily treatment approved for management of post-herpetic neuralgia (PHN) and has been licensed to Abbott Products Inc. The company also has a robust pipeline including one in Phase 3 clinical development, and other product candidates in its early stage pipeline. Product candidate Serada® is in Phase 3 clinical development for menopausal hot flashes. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website,

Contact Information